NovaBridge unit Visara licenses HT006.2.2 nerve growth factor therapy for neurotrophic keratitis outside Greater China
Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, secured an exclusive license to develop VIS-102 for neurotrophic keratitis. Rights cover worldwide markets excluding Greater China; VIS-102 is a modified recombinant human nerve growth factor designed for refrigerated, ready-to-use single dose